# Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Canonical URL: https://biopharmsignal.com/news/FATE/fate-therapeutics-reports-new-employee-inducement-awards-under-nasdaq-listing-ru-842a053c
Ticker: FATE
Company: Fate Therapeutics
Source: Fate Therapeutics
Published: 2026-06-02 20:05 EST
Original Source URL: https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-reports-new-employee-inducement-awards-16
## Summary

The Investor Relations website contains information about Fate Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.

## Article Body
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune diseases, today announced that on June 1, 2026, the Company granted restricted stock units (RSUs) representing 67,300 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company’s Board of Directors and granted under the Company’s Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each vesting date.

About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com .

Contact: Ryan Douglas Fate Therapeutics, Inc. IR@fatetherapeutics.com
## Recent Company News
- 2026-07-09 12:30 EST — [Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate](https://biopharmsignal.com/news/FATE/fate-therapeutics-receives-fda-clearance-of-investigational-new-drug-application-5f43a8db) — Source: Fate Therapeutics
- 2026-07-06 12:30 EST — [Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting](https://biopharmsignal.com/news/FATE/fate-therapeutics-to-present-preliminary-clinical-data-of-ft819-off-the-shelf-ca-2ca1e01e) — Source: Fate Therapeutics
- 2026-07-01 20:05 EST — [Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences](https://biopharmsignal.com/news/FATE/fate-therapeutics-to-participate-in-upcoming-third-quarter-2026-conferences-457e2808) — Source: Fate Therapeutics
- 2026-06-15 12:30 EST — [Fate Therapeutics Appoints Laura Hamill to Board of Directors](https://biopharmsignal.com/news/FATE/fate-therapeutics-appoints-laura-hamill-to-board-of-directors-d47c62a6) — Source: Fate Therapeutics
- 2026-06-04 12:30 EST — [Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting](https://biopharmsignal.com/news/FATE/fate-therapeutics-showcases-data-from-ft819-and-ft839-programs-at-the-european-c-c6edd4ee) — Source: Fate Therapeutics
## Related News
- 2026-07-22 21:05 EST — SUPN — [Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026](https://biopharmsignal.com/news/SUPN/supernus-pharmaceuticals-to-announce-second-quarter-2026-financial-results-and-h-58b4f63d)
- 2026-07-22 20:15 EST — MOH — [Molina Healthcare Reports Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/MOH/molina-healthcare-reports-second-quarter-2026-financial-results-343e2d32)
- 2026-07-22 20:15 EST — BFRG — [BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-the-btig-virtual-biotechnology-conference-5880a10e)
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)